Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: a post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria

被引：0

作者：

Raab, Marc ^{[1
]}

Manier, Salomon ^{[2
]}

Prince, H. Miles ^{[3
]}

Nooka, Ajay ^{[4
]}

Kaedbey, Rayan ^{[5
]}

Hillengass, Jens ^{[6
]}

Ishida, Tadao ^{[7
]}

Sullivan, Sharon ^{[8
]}

Conte, Umberto ^{[8
]}

Leip, Eric ^{[8
]}

Viqueira, Andrea ^{[9
]}

Raje, Noopur ^{[10
]}

机构：

[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany

[2] Univ Lille, Ctr Hosp Univ Lille, Lille, France

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA USA

[5] McGill Univ, Montreal, PQ, Canada

[6] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[7] Japanese Red Cross Med Ctr, Tokyo, Japan

[8] Pfizer Inc, New York, NY USA

[9] Pfizer SLU, Madrid, Spain

[10] Massachusetts Gen Hosp, Boston, MA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-307

引用

页码：S207 / S208

页数：2

共 50 条

[31] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
Grosicki, Sebastian
Mellqvist, Ulf-Henrik
Pruchniewski, Lukasz
Crafoord, Jacob
Trudel, Suzanne
Min, Chang-Ki
White, Darrell
Alegre, Adrian
Hansson, Markus
Ikeda, Takashi
Sunami, Kazutaka
Leip, Eric
Kudla, Arthur
Finn, Gregory
Koh, Youngil
BLOOD, 2022, 140 : 4407 - 4408
[32] Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies
Raab, M. S.
Hanel, M.
Nooka, A. K.
Lesokhin, A. M.
Mohty, M.
Niesvizky, R.
Maisel, C.
Arnulf, B.
Larson, S. M.
Varshavsky-Yanovsky, A. N.
Leleu, X.
Karlin, L.
Vesole, D. H.
Bahlis, N. J.
de larrea, Fernandez C.
Raje, N.
Leip, E.
Conte, U.
Elmeliegy, M.
Viqueira, A.
Manier, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 232 - 232
[33] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Lesokhin, Alexander M.
Arnulf, Bertrand
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Tomasson, Michael H.
Rodriguez-Otero, Paula
Quach, Hang
Raje, Noopur S.
Iida, Shinsuke
Raab, Marc-Steffen
Czibere, Akos
Sullivan, Sharon
Leip, Eric
Viqueira, Andrea
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms intriple-class refractory multiple myeloma (vol 20, pg 1175, 2024)
Costa, Luciano J.
LeBlanc, Thomas W.
Tesch, Hans
Sonneveld, Pieter
Kyle, Ryan P.
Sinyavska, Liliya
Hlavacek, Patrick
Meche, Aster
Ren, Jinma
Schepart, Alex
Aydin, Didem
Nador, Guido
DiBonaventura, Marco daCosta
FUTURE ONCOLOGY, 2024,
[35] Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
Suzuki, Kenshi
Min, Chang-Ki
Kim, Kihyun
Lee, Je-Jung
Shibayama, Hirohiko
Ko, Po-Shen
Huang, Shang-Yi
Li, Sin-Syue
Ding, Bifeng
Khurana, Monica
Iida, Shinsuke
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (06) : 653 - 663
[36] Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
Kenshi Suzuki
Chang-Ki Min
Kihyun Kim
Je-Jung Lee
Hirohiko Shibayama
Po-Shen Ko
Shang-Yi Huang
Sin-Syue Li
Bifeng Ding
Monica Khurana
Shinsuke Iida
International Journal of Hematology, 2021, 114 : 653 - 663
[37] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
Raab, M. S.
Haenel, M.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Prince, H. M.
Niesvizky, R.
Rodriguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Jethava, Y.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Raje, N.
Iida, S.
Leip, E.
Conte, U.
Czibere, A.
Viqueira, A.
Lesokhin, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
[38] Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis
Jakubowiak, Andrzej
Usmani, Saad Z.
Berdeja, Jesus G.
Agha, Mounzer
Cohen, Adam D.
Hari, Parameswaran
Schecter, Jordan M.
Madduri, Deepu
Yeh, Tzu-Min
Olyslager, Yunsi
Banerjee, Arnob
Jackson, Carolyn C.
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Zhou, Changwei
Geng, Dong
Pacaud, Lida
Lin, Yi
Martin, Thomas
Jagannath, Sundar
BLOOD, 2021, 138
[39] Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience
Grajales-Cruz, Ariel F.
Hansen, Doris K.
Castaneda, Omar
Graeter, Allison
Vazquez-Martinez, Mariola A.
Modukuri, Shrikar
De Avila, Gabriel
Denson, Ariel
Fadul, Julia
Blue, Brandon
Lopez, Blanca
Harvey, Kristy
Thapa, Shrinjaya B.
Tobon, Katherine
Melnick, Parker
Ionescu, Filip
Liu, Hien
Ochoa-Bayona, Jose L.
Freeman, Ciara Louise
Locke, Frederick
Nishihori, Taiga
Shain, Kenneth H.
Alsina, Melissa
Baz, Rachid
BLOOD, 2024, 144 : 7832 - 7833
[40] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →